patients

TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients’ Access to Life-Changing Medicines

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.   CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/…

2 months ago

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

2 months ago

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

2 months ago

ZIWIG ENDOTEST: FAST-TRACK REIMBURSEMENT FOR 25 000 PATIENTS FOR FIRST SALIVA TEST TO DIAGNOSE ENDOMETRIOSIS IN 80 MEDICAL CENTERS IN FRANCE

LYON, France, Feb. 11, 2025 /PRNewswire/ -- Ziwig, a French biotech company committed to advancing women's health, announces the fast-track reimbursement…

2 months ago

Philips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patients

February 10, 2025 Groundbreaking program that provides technology and training is reducing the impact of stroke, one of the leading…

2 months ago

EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…

2 months ago

Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…

2 months ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trialin Patients with Idiopathic Pulmonary Fibrosis

February 07, 2025 16:58 ET  | Source: Pliant Therapeutics, Inc. Following DSMB recommendation, the Company has voluntarily paused enrollment and…

2 months ago